Ahmed Nader1, Nael M Mostafa2, Farah Ali3, Mohamad Shebley2. 1. AbbVie Clinical Pharmacology and Pharmacometrics, 1 North Waukegan Road, North Chicago, IL, 60064, USA. ahmed.nader@Abbvie.com. 2. AbbVie Clinical Pharmacology and Pharmacometrics, 1 North Waukegan Road, North Chicago, IL, 60064, USA. 3. AbbVie Clinical Development, North Chicago, IL, USA.
Abstract
BACKGROUND AND OBJECTIVE: Elagolix is an oral, non-peptide, gonadotropin-releasing hormone receptor antagonist. It is approved for the treatment of moderate-to-severe pain associated with endometriosis and is being investigated for the treatment of heavy menstrual bleeding associated with uterine fibroids. Use of low-dose hormonal add-back therapy can reduce hypoestrogenic effects associated with elagolix, thus there is a need to determine if there is a pharmacokinetic interaction between elagolix and low-dose hormonal add-back therapy. METHODS: Two multiple-dose, open-label, single-sequence, non-randomized studies for elagolix 300 mg twice daily with oral (n = 24) and transdermal (n = 36) low-dose add-back therapy (estradiol [E2]/norethindrone acetate [NETA]; 1 mg/0.5 mg oral and 0.51 mg/4.8 mg transdermal) in healthy postmenopausal women were conducted, with pharmacokinetic sampling for E2, estrone (E1), and NETA up to 72 or 96 h after dosing. Pharmacokinetic parameters for hormones were estimated using noncompartmental methods. RESULTS: No change in norethindrone maximum plasma concentration or area under the concentration-time curve was observed when oral E2/NETA was administered with elagolix. For E2, there was a 2-fold increase in maximum plasma concentration and a 1.5-fold increase in the area under the concentration-time curve, and for E1 there was a 1.7-fold increase in maximum plasma concentration when oral E2/NETA was administered with elagolix. Exposures for norethindrone, E2, and E1 were unchanged when transdermal E2/NETA was applied with elagolix administration. CONCLUSIONS: Although changes in E2/E1 exposures were observed when oral E2/NETA was co-administered with elagolix, these changes are not considered clinically relevant; and no dose adjustments are recommended when elagolix is co-administered with oral or transdermal low-dose add-back therapy.
BACKGROUND AND OBJECTIVE:Elagolix is an oral, non-peptide, gonadotropin-releasing hormone receptor antagonist. It is approved for the treatment of moderate-to-severe pain associated with endometriosis and is being investigated for the treatment of heavy menstrual bleeding associated with uterine fibroids. Use of low-dose hormonal add-back therapy can reduce hypoestrogenic effects associated with elagolix, thus there is a need to determine if there is a pharmacokinetic interaction between elagolix and low-dose hormonal add-back therapy. METHODS: Two multiple-dose, open-label, single-sequence, non-randomized studies for elagolix 300 mg twice daily with oral (n = 24) and transdermal (n = 36) low-dose add-back therapy (estradiol [E2]/norethindrone acetate [NETA]; 1 mg/0.5 mg oral and 0.51 mg/4.8 mg transdermal) in healthy postmenopausal women were conducted, with pharmacokinetic sampling for E2, estrone (E1), and NETA up to 72 or 96 h after dosing. Pharmacokinetic parameters for hormones were estimated using noncompartmental methods. RESULTS: No change in norethindrone maximum plasma concentration or area under the concentration-time curve was observed when oral E2/NETA was administered with elagolix. For E2, there was a 2-fold increase in maximum plasma concentration and a 1.5-fold increase in the area under the concentration-time curve, and for E1 there was a 1.7-fold increase in maximum plasma concentration when oral E2/NETA was administered with elagolix. Exposures for norethindrone, E2, and E1 were unchanged when transdermal E2/NETA was applied with elagolix administration. CONCLUSIONS: Although changes in E2/E1 exposures were observed when oral E2/NETA was co-administered with elagolix, these changes are not considered clinically relevant; and no dose adjustments are recommended when elagolix is co-administered with oral or transdermal low-dose add-back therapy.
Authors: Ahmed M Soliman; Savita Bakhshi Anand; Karin S Coyne; Jane Castelli-Haley; Michael Snabes; Charlotte D Owens Journal: J Occup Environ Med Date: 2017-10 Impact factor: 2.162
Authors: Hugh S Taylor; Linda C Giudice; Bruce A Lessey; Mauricio S Abrao; Jan Kotarski; David F Archer; Michael P Diamond; Eric Surrey; Neil P Johnson; Nelson B Watts; J Chris Gallagher; James A Simon; Bruce R Carr; W Paul Dmowski; Nicholas Leyland; Jean P Rowan; W Rachel Duan; Juki Ng; Brittany Schwefel; James W Thomas; Rita I Jain; Kristof Chwalisz Journal: N Engl J Med Date: 2017-05-19 Impact factor: 91.245
Authors: Bruce R Carr; Elizabeth A Stewart; David F Archer; Ayman Al-Hendy; Linda Bradley; Nelson B Watts; Michael P Diamond; Jingjing Gao; Charlotte D Owens; Kristof Chwalisz; W Rachel Duan; Ahmed M Soliman; Matthew B Dufek; James A Simon Journal: Obstet Gynecol Date: 2018-11 Impact factor: 7.661
Authors: William D Schlaff; Ronald T Ackerman; Ayman Al-Hendy; David F Archer; Kurt T Barnhart; Linda D Bradley; Bruce R Carr; Eve C Feinberg; Sandra M Hurtado; JinHee Kim; Ran Liu; R Garn Mabey; Charlotte D Owens; Alfred Poindexter; Elizabeth E Puscheck; Henry Rodriguez-Ginorio; James A Simon; Ahmed M Soliman; Elizabeth A Stewart; Nelson B Watts; Ozgul Muneyyirci-Delale Journal: N Engl J Med Date: 2020-01-23 Impact factor: 91.245
Authors: Mohamad Shebley; Akshanth R Polepally; Ahmed Nader; Juki W Ng; Insa Winzenborg; Cheri E Klein; Peter Noertersheuser; Megan A Gibbs; Nael M Mostafa Journal: Clin Pharmacokinet Date: 2020-03 Impact factor: 6.447